GlaxoSmithKline Finds ‘Synta’ergy With $1 Billion Deal For Oncology Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Synta CEO tells “The Pink Sheet” DAILY deal will allow firm to move other pipeline candidates through development on its own.
You may also be interested in...
Elesclomol's Phase III Fizzle Leaves Synta In Need Of Alternatives
Suspension of Synta/GlaxoSmithKline's Phase III oncology candidate elesclomol amid signs of higher mortality has left developer Synta with a gaping late-stage pipeline hole and in need of a new business plan
Elesclomol's Phase III Fizzle Leaves Synta In Need Of Alternatives
Suspension of Synta/GlaxoSmithKline's Phase III oncology candidate elesclomol amid signs of higher mortality has left developer Synta with a gaping late-stage pipeline hole and in need of a new business plan
Elesclomol’s Phase III Fizzle Leaves Synta In Need of Plan B
News on melanoma could put the biotech’s lucrative partnership with GlaxoSmithKline in jeopardy.